Journal article
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
G Allevi, C Strina, D Andreis, V Zanoni, L Bazzola, S Bonardi, C Foroni, M Milani, MR Cappelletti, F Gussago, S Aguggini, R Giardini, M Martinotti, SB Fox, AL Harris, A Bottini, A Berruti, D Generali
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2013
DOI: 10.1038/bjc.2013.151
Open access
Abstract
Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis an..
View full abstract